Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use

Keyphrases

• A1 Receptor 100%
• Type 2 Diabetes Mellitus (T2DM) 100%
• Chronic Kidney Disease 100%
• Receptor Agonist 100%
• Glucagon-like 100%
• Finerenone 100%
• Confidence Interval 33%
• Hazard Ratio 33%
• Composite Outcome 16%
• Cardiovascular Mortality 8%
• Placebo 8%
• AIMS™ 8%
• Nonfatal Myocardial Infarction 8%
• Cardiovascular Outcomes 8%
• Type 2 Diabetic Patients 8%
• Renin-angiotensin System Blockade 8%
• Hyperkalemia 8%
• Potential Gains 8%
• Pooled Analysis 8%
• Kidney 8%
• Heart Failure Hospitalization 8%
• Nonfatal Stroke 8%
• Kidney Failure 8%
• Renal Death 8%
• Copyright 8%
• Diabetic Kidney Disease 8%
• Modifying Effect 8%
• EGFR Decline 8%
• Glucagon-like peptide-1 Receptor (GLP-1R) 8%
• Heart-kidney 8%
• Kidney Outcomes 8%
• Overall Safety 8%
• Cardiorenal Benefits 8%
• FIDELIO-DKD 8%
• FIGARO 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Insulin Dependent Diabetes Mellitus 100%
• Chronic Kidney Failure 100%
• Glucagon Like Peptide 1 Receptor Agonist 100%
• Finerenone 100%
• Heart Infarction 8%
• Placebo 8%
• Renin 8%
• Angiotensin 8%
• Heart Failure 8%
• Hyperkalemia 8%
• Kidney Failure 8%